
The Public Chafed the Last Time the GOP Tried to Cut Medicaid
Will This Time be Different? Past Health Bills Hold Clues
Blog Post
On February 7, 2025, the Trump administration abruptly announced a cap on indirect rates for National Institutes of Health (NIH) awards, limiting them to 15%—a move currently on hold following a district court injunction temporarily blocking the policy. While NIH funding has long enjoyed bipartisan support, it is once again under threat. Today’s Chart of the Day places this controversy in a broader context by showing how NIH funding has already eroded over the past two decades.
In a recent JAMA Viewpoint, Penn LDI Senior Fellow Nadir Yehya notes that between 1998 and 2003, the NIH budget doubled in nominal terms—the actual dollar amounts spent or allocated each year, not adjusted for inflation. This period was marked by robust bipartisan investment in biomedical research. But that rapid growth proved short-lived. Since peaking in 2003, the NIH budget has stagnated or declined in real dollars, meaning figures adjusted for inflation using the Consumer Price Index (CPI), even as the U.S. population grew by nearly 50 million and research costs rose sharply.
By 2024, the NIH budget in real terms stood about 7.4% lower than its 2003 peak, underscoring a sustained failure to keep pace with inflation and the rising cost of scientific research. As policymakers weigh potential cuts, this inflation-adjusted trajectory is a critical data point for setting funding priorities that reflect the long-term needs of the biomedical research enterprise.
The study, “NIH Funding Has Stagnated Since 2003,” was published on April 16, 2025, in JAMA. Authors include Nadir Yehya.
Will This Time be Different? Past Health Bills Hold Clues
Supplement to Response to Request for Technical Assistance
But Many Other Factors Played a Role in Denying Loans, LDI Fellow Says
A Simple Change to Clinicians’ Prescribing System Reduced Prescription Disparities by Race, Ethnicity, Insurance Type, and Income
Offit and Buttenheim Criticize HHS Placebo Trial Mandate as Unethical, Misleading, and a Threat to Vaccine Confidence
AcademyHealth Honor Recognizes Early Career Researchers of Exceptional Potential